Ivonescimab plus paclitaxel for stomach cancer after first-line therapy
Part of Cancer clinical trials.
This trial tests a new drug combination (ivonescimab plus paclitaxel) as a second treatment for advanced stomach cancer. It's for people whose cancer grew after first-line therapy with a checkpoint inhibitor plus platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) that has progressed after your first treatment.
- You previously received a combination of a PD-1 or PD-L1 checkpoint inhibitor drug and platinum-based chemotherapy for at least 12 weeks as your first therapy.
- You have not had a taxane chemotherapy drug (like paclitaxel) or a targeted therapy called ramucirumab before.
- You are between 18 and 75 years old and have good overall health (able to perform daily activities).
- Your vital organs (liver, kidneys, bone marrow, heart) are functioning well enough based on standard lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of two drugs, cadonilimab and a type of paclitaxel, for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to prior immunotherapy (PD-1/PD-L1 inhibitors). The goal is to see if this new combination can help shrink tumors or slow disease progression.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. The drugs are designed to help your immune system fight the cancer while chemotherapy attacks it directly.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial tests a combination of three drugs (sintilimab, ramucirumab, and paclitaxel) for people with stomach cancer that returned soon after finishing initial chemotherapy. The goal is to see if this combination can help control the cancer and improve outcomes.
Hear when a new Gastric (Cardia, Body) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.